Surrozen, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Surrozen, Inc./DE (SRZN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 779.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 778.26K shares, a 153.51% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 738.00 shares, a 99.81% decline year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 50.00K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 45.00K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 794.00K shares, a 307651.94% increase from fiscal 2024.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 258.00 shares, a 115.00% increase from fiscal 2023.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 120.00 shares, a 94.54% decline from fiscal 2022.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.20K shares, a 99.77% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 778.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 779.00K shares 10-Q · filed 2026-08-06 | 829.00K shares derived: sum of 3 quarters · filed 2026-08-06 | 874.00K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 738.00 shares 10-Q · filed 2026-05-06 | 50.74K shares derived: sum of 2 quarters · filed 2026-05-06 | 95.74K shares derived: sum of 3 quarters · filed 2026-05-06 | 402.74K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 50.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 95.00K shares derived: sum of 2 quarters · filed 2026-03-23 | 402.00K shares derived: sum of 3 quarters · filed 2026-03-23 | 794.00K shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 45.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 352.00K shares derived: sum of 2 quarters · filed 2025-11-07 | 744.00K shares 10-Q · filed 2025-11-07 | 486.26K shares derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | 307.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | 699.00K shares 10-Q · filed 2025-08-08 | 441.26K shares derived: sum of 3 quarters · filed 2025-08-08 | 441.26K shares derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | 392.00K shares 10-Q · filed 2025-05-09 | 134.26K shares derived: sum of 2 quarters · filed 2025-05-09 | 134.26K shares derived: sum of 3 quarters · filed 2025-05-09 | 392.26K shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | -257.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -257.74K shares derived: sum of 2 quarters · filed 2025-03-31 | 258.00 shares derived: sum of 3 quarters · filed 2025-03-31 | 258.00 shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 258.00K shares derived: sum of 2 quarters · filed 2024-11-06 | 258.00K shares 10-Q · filed 2024-11-06 | -1.55M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 258.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 258.00K shares 10-Q · filed 2024-08-12 | -1.55M shares derived: sum of 3 quarters · filed 2024-08-12 | -1.55M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-08 | -1.80M shares derived: sum of 2 quarters · filed 2024-05-08 | -1.80M shares derived: sum of 3 quarters · filed 2024-05-08 | -1.48K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | -1.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -1.80M shares derived: sum of 2 quarters · filed 2024-04-10 | -1.48K shares derived: sum of 3 quarters · filed 2024-04-10 | 120.00 shares 10-K · filed 2024-04-10 |
| 2023-09-30 | 1.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 1.80M shares derived: sum of 2 quarters · filed 2023-11-08 | 1.80M shares 10-Q · filed 2023-11-08 | 1.81M shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 1.80M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 1.80M shares 10-Q · filed 2023-08-09 | 1.80M shares derived: sum of 3 quarters · filed 2023-08-09 | 1.80M shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 1.60K shares 10-Q · filed 2023-05-10 | 1.70K shares derived: sum of 2 quarters · filed 2023-05-10 | 2.04K shares derived: sum of 3 quarters · filed 2023-05-10 | 2.23K shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 92.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 437.00 shares derived: sum of 2 quarters · filed 2023-03-31 | 631.00 shares derived: sum of 3 quarters · filed 2023-03-31 | 2.20K shares 10-K · filed 2023-03-31 |
| 2022-09-30 | 345.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 539.00 shares derived: sum of 2 quarters · filed 2022-11-14 | 2.11K shares 10-Q · filed 2022-11-14 | 107.66K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 194.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.76K shares 10-Q · filed 2022-08-11 | 107.31K shares derived: sum of 3 quarters · filed 2022-08-11 | |
| 2022-03-31 | 1.57K shares 10-Q · filed 2022-05-11 | 107.12K shares derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2021-12-31 | 105.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 945.53K shares 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 839.97K shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |